Before You Continue
Coast Performance Medicine is a physician-led medical practice. By entering this website, you acknowledge and agree to the following:
- You are at least 18 years of age.
- All content on this site is provided for general informational and educational purposes only and does not constitute medical advice.
- No physician–patient relationship is created by viewing this website or submitting a form.
- All therapies described — including peptide, hyperbaric, photobiomodulation, and IV protocols — are prescribed and administered only after individual clinical evaluation by a licensed physician.
- Statements on this site have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease.
- Coast Performance Medicine provides care only to patients physically located in Florida at the time of service. Nothing here is an offer to provide medical care where our physicians are not licensed.
Research & evidence
An honest accounting of what the literature supports, what it doesn’t yet, and how that difference changes the way we prescribe and monitor.
What the evidence actually supports
Peptide therapy occupies an unusual position. A few compounds are FDA-approved with substantial human trial data behind them. Many more have promising preclinical work — cell culture and animal models — but limited controlled human evidence. A responsible practice has to be honest about which is which.
Below is how CPM categorises the evidence base for the compounds in our library. This framing shapes how we counsel patients, how conservatively we dose, and how closely we monitor.
FDA-approved
Approved for at least one indication with human trial data supporting safety and efficacy. Tesamorelin and Sermorelin fall here. Use outside the approved indication is still off-label.
Human data, unapproved
Published human studies exist, often small or in specific populations, but the compound lacks approval for the use discussed. PT-141, Thymosin Alpha-1, and MK-677 sit in this tier.
Preclinical / emerging
Mechanistically plausible with animal or in-vitro support, but thin human evidence. BPC-157, TB-500, MOTS-c, SLU-PP-332, and Epithalon belong here. Counselling and monitoring are correspondingly more conservative.
How we handle Tier 3
Emerging evidence is not a reason to refuse a therapy outright, but it does change the conversation. For Tier 3 compounds we set explicit expectations, start at conservative doses, define a review point in advance, and stop if the objective markers don’t move. A protocol that isn’t working gets discontinued rather than escalated.
What we won’t claim
You will not find outcome guarantees, before-and-after promises, or disease-treatment claims anywhere in this section. Several compounds here are studied for conditions they are not approved to treat, and the honest summary of much of this literature is that larger controlled trials are still needed.
If you want to read the primary literature yourself, ask at your consultation. Your physician can point you to the specific trials and reviews behind any compound you’re considering — including the studies that argue against it.
Ongoing review
The evidence base here moves quickly. CPM reviews the literature underpinning our protocol library periodically and adjusts tiering, dosing guidance, and patient counselling as new data lands — in both directions.
Get Started
Find the protocol that fits you
Peptide therapy works when it’s matched to your biology and your goals. Book an assessment and we’ll build it from your labs, not a catalog.
Book Your Consultation